MODULE 3: Advances in safety in the treatment of PCa

Presenter(s)
Prof. Dr. A.S. Merseburger (DE)
Dr. A. So (CA)
Ass. Prof. K Zhang (US)
Date & time
Wednesday, 1 September 2021, 18:30 - 19:30 CEST
 
 
 

MODULE 3: Advances in safety in the treatment of PCa

Pre-recording by Dr. Alan So - CUA
Safety data - GNRH Analogues, focus on CVD risk profile 
- PCa therapy induced CVD toxicity
- ADT plus newer antiandrogens
- Radiotherapy alone or in combination
- Data from latest trials – HERO

Pre-recording by Prof. Axel Merseburger - EAU
Safety data – mHSPC therapy and CVD risk profile
- Data from animal models & basic research
- Other treatment modalities (chemotherapy, surgery, ADT alone or in combination)                                       
- New treatment modalities and CVD toxicity

Live webinar 
Case study (incl Cardiac biomarkers) by Ass. Prof. Katie Zhang - ICOS
Q&A by panellists Dr. Alan So & Prof. Axel Merseburger

At a glance
Publication date: September 2021
Available languages: English
Topic: Prostate Cancer
CME: This webinar is accredited with 1 European CME credit (ECMEC®) upon completion of the questionnaire after attending the live webinar
Duration: Approx. 60  minutes

This educational activity has been funded by Ferring Pharmaceutical. The educational programme of this online activity has been a collaboration with Ferring Pharmaceutical, but independently developed and approved by the Canadian Urological Association, the International Cardio-Oncology Society together with the European Association of Urology

Registration for this webinar is now closed

The recording will be available at www.uroweb.org/webinars 24 hours after the webinar has taken place.

Back to UROwebinar overview
Contact information
European Association of Urology
Registration Department
+31 (0)26 389 1751